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Ischemic stroke is among the leading causes of disability and death worldwide. In
acute ischemic stroke, the rapid recanalization of occluded cranial vessels is the primary
therapeutic aim. However, experimental data (obtained using mostly the transient middle
cerebral artery occlusionmodel) indicates that progressive stroke can still develop despite
successful recanalization, a process termed “reperfusion injury.” Mounting experimental
evidence suggests that platelets and T cells contribute to cerebral ischemia/reperfusion
injury, and ischemic stroke is increasingly considered a thrombo-inflammatory disease.
The interaction of von Willebrand factor and its receptor on the platelet surface,
glycoprotein Ib, as well as many activatory platelet receptors and platelet degranulation
contribute to secondary infarct growth in this setting. In contrast, interference with
GPIIb/IIIa-dependent platelet aggregation and thrombus formation does not improve
the outcome of acute brain ischemia but dramatically increases the susceptibility
to intracranial hemorrhage. Here, we summarize the current understanding of the
mechanisms and the potential translational impact of platelet contributions to cerebral
ischemia/reperfusion injury.
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INTRODUCTION
Stroke is a leading cause of disability and death worldwide. The majority of strokes are caused
by cerebral ischemia, only ∼20% of strokes are caused by primary intracerebral hemorrhage (1).
The primary therapeutic goal in acute ischemic stroke is the rapid re-establishment of blood flow
by thrombolysis or mechanical thrombectomy. The invention of thrombectomy has dramatically
increased the rate of successful recanalization up to 80% and improved neurological sequelae, but
the number needed to treat (NNT) for a good outcome is still high, around 4–6 (2, 3). It is known
from experimental stroke models, that infarcts can grow despite successful reperfusion, which is
commonly referred to as ischemia/reperfusion injury (I/RI). In humans, there are many possible
reasons for unfavorable outcomes after recanalization such as advanced stroke development with
low ASPECTS scores already at treatment entry or bleeding complications, but recent clinical trials
testing immune-modulatory drugs in acute stroke indicate that infarcts can grow after restoration
of cerebral blood flow also in humans (4, 5), although the occurrence of reperfusion injury in the
human brain is less clear than in experimental animal models (6). However, the process of further
tissue injury upon reconstitution of blood flow is known to apply to different other organ systems
such as heart, liver and kidney (7). The middle cerebral artery (MCA) is the most commonly
affected blood vessel in human occlusive/ischemic stroke. A broad range of MCAO models has
been developed [reviewed in (8)] but no animal model perfectly reflects the disease under study and
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each model has strengths and limitations trying to reproduce
the complex heterogeneous nature of stroke in humans. To
study the underlying pathomechanisms of I/RI in the brain, the
transient middle cerebral artery occlusion (tMCAO) model of
focal cerebral ischemia is widely used, mostly in rodents (9).
Advantages and disadvantages of the tMCAO model have been
discussed in a recent review (10). In this model, a filament is
usually inserted via the internal carotid artery to occlude the
MCA for defined time periods, most commonly for 1 h, resulting
in complete infarction of theMCA territory. Importantly, infarcts
are not fully developed immediately after recanalization but
evolve in the reperfusion phase. Numerous experimental studies
have established a contribution of platelets and immune cells, in
particular T cells, in this cerebral I/RI (11). Therefore, ischemic
stroke is now considered a thrombo-inflammatory disease (12).
The contribution of neuro-inflammation to cerebral damage
following ischemic stroke has been recently reviewed (11, 13, 14),
thus, in this review, we focus on the contribution of platelets.
The initial capture of circulating platelets to exposed
components of the extracellular matrix (ECM) at sites of
vascular injury or inflammation is mediated by the interaction
of the glycoprotein (GP) Ib-IX-V receptor complex with
von Willebrand factor (vWF) (15). GPIbα-vWF interactions
are essential for initial platelet tethering under high shear
flow conditions, found e.g., in stenosed arteries, but are only
transient and too weak to mediate firm platelet adhesion,
but rather decelerate and recruit platelets from the blood
stream, which is reflected by the “rolling” of platelets on
the vessel wall (16). These “rolling” platelets can interact via
their activatory platelet receptors with the corresponding
ligands. Platelet activation is mainly triggered through two
major signaling pathways, depending on the initial stimulus:
signaling via G-protein coupled receptors (GPCRs) (17, 18)
or the (hem)immunoreceptor tyrosine-based activation motif
(ITAM)-bearing receptors. Both signaling pathways culminate in
activation of intracellular signaling cascades involving a rise in
cytosolic Ca2+ concentration, cytoskeletal rearrangements,
mobilization of α- and dense granules and subsequent
release of secondary platelet agonists and the conformational
change of integrin adhesion receptors, most notably αIIbβ3
(GPIIb/IIIa), from a low to a high affinity state, thereby
mediating firm platelet adhesion, aggregation and thrombus
growth (19).
Efficient blockade of GPIIb/IIIa, leading to abolished
platelet aggregation (20, 21), led to intracranial hemorrhage
and the treatment did not reduce cerebral infarct sizes in
mice (22). Similarly, in a clinical trial, anti-GPIIb/IIIa
treatment of patients in acute ischemic stroke was not
protective (23). These data exclude platelet aggregation as a
critical pathomechanism underlying stroke progression after
recanalization and demonstrate that cerebral I/RI cannot
simply be explained by secondary thrombotic events in the
microcirculation. This does not exclude the appearance of
micro-thrombi in the cerebral microvasculature after ischemic
stroke, as thrombo-inflammation might be associated with re-
thrombosis but does not require these thrombotic events to cause
tissue damage.
GPIbα-vWF INTERACTIONS
GPIbα is part of the GPIb-IX-V receptor complex that is
expressed on the platelet surface. The GPIb subunit binds
many ligands, including its major ligand vWF, P-selectin,
macrophage antigen 1 (Mac-1), and the coagulation factors
XI, XII, and thrombin (24). At high shear rates, prevailing
in small arterioles or stenosed arteries, initial adherence of
platelets to the ECM is mediated by the interaction of GPIbα
and vWF (15). Blocking the vWF binding site on GPIbα (using
Fab fragments of the p0p/B antibody) has been shown to
abolish platelet adhesion to the injured carotid artery wall and
protects mice from occlusive thrombus formation in vivo (25).
Remarkably, treatment of mice with p0p/B Fab lead to reduced
infarct sizes, sustained reperfusion and a better neurological
outcome after tMCAO, irrespective whether treatment was
given 1 h before or after vessel occlusion (see Figure 1) (22,
26). Although mice show a prolonged bleeding time after
treatment with the GPIbα blocking Fab, MRI analysis excluded
the presence of intracerebral hemorrhages (22). These findings
could be reproduced using a transgenic mouse model, where the
ectodomain of the human interleukin 4 receptor is expressed
instead of the ectodomain of GPIbα (IL4Rα/GPIbα), leading to
GPIbα deficiency without the loss of the receptor complex from
the platelet surface (27–30). Likewise, vWF-deficient mice that
were subjected to the tMCAO model had smaller infarcts and
less neurological damage than the respective controls, without
showing intracranial bleedings (31). Genetic reconstitution of
plasma vWF levels restored the susceptibility of these mice
to ischemic stroke (31). Of note, despite only constituting
20% of the total vWF protein (32), platelet vWF alone was
sufficient to render mice susceptible to experimental stroke (33).
Targeting of GPIbα downstream signaling also appears to be
beneficial for the outcome after tMCAO, since deficiency or
inhibition of phospholipase (PL) D1 and D2 protected mice from
acute ischemic stroke (34–36). Further, GPIbα-blockade reduced
cerebral damage in experimental stroke of aged and comorbid
animals (e.g., atherosclerotic Ldlr−/−, diabetic or hypertensive
mice) indicating that GPIbα-blockade may be a therapeutic
option in the future for patients with accompanying common
cardiovascular diseases (37).
Studies performed in stroke patients revealed that genetic
alterations in the GP1bA gene and increased serum levels of vWF
are risk factors for stroke (38, 39), and a predictive factor for long
termmortality after acute stroke (40). VWF is a large, multimeric
protein (up to 20,000 kDa) synthesized in endothelial cells and
megakaryocytes that is highly thrombogenic. In the plasma the
enzyme A disintegrin and metalloprotease with thrombospondin
type 1 repeats 13 (ADAMTS13) cleaves vWF multimers into
smaller, less active fragments, thereby reducing vWF activity.
Mice lacking ADAMTS13 suffered from severely worsened
ischemic brain damage following experimental stroke (41, 42),
while intravenous administration of recombinant ADAMTS13
prior to reperfusion reduced infarct size and improved functional
outcome after focal cerebral ischemia (41). Autoantibodies
against ADAMTS13 as detected in most patients with acquired
thrombotic thrombocytopenic purpura (TTP), or mutations in
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FIGURE 1 | Inhibition of platelet activation or degranulation, but not GPIIb/IIIa blockade results in reduced infarct sizes in experimental stroke. Blockade or genetic
deficiency of GPIbα, GPVI, P2Y1, P2Y12, PAR1, or PAR4 reduces infarct sizes following cerebral ischemia/reperfusion injury. Likewise, lack of either dense (δ) or
α-granule secretion improves the outcome following experimental stroke. In contrast, combined loss of dense and α-granule secretion or GPIIb/IIIa-blockade is
accompanied by intracranial hemorrhage. See text for details.
the ADAMTS13 gene as found in patients with hereditary TTP
are associated with an increased risk of thrombotic occlusion of
micro vessels in different organs, including the brain (43).
Collectively, these studies argue for the GPIb-vWF axis as
an attractive target for stroke therapy. Inhibitory toxins and
antibodies or aptamers targeting GPIb-vWF interactions have
been designed and are currently tested in preclinical or clinical
studies for different applications [reviewed as part of (44)].
Anfibatide, a snake venom-derived GPIb antagonist, led to a
dose dependent reduction in infarct sizes without inducing
intracranial hemorrhages when tested in mice using the tMCAO
model (45) and has successfully completed a phase I clinical
study (46). Although the anti-vWF nanobody caplacizumab
was initially approved in 2018 as treatment for thrombotic
thrombocytopenic purpura (47), it was also shown to be an
effective therapy in a stroke model using guinea pigs (48),
indicating that it might also be beneficial in stroke therapy. One
additional promising feature of strategies targeting the GPIb-
vWF axis is that they have been shown to exert thrombolytic
activity (48–50). Thus, in addition to dampening thrombo-
inflammation (22, 51), also the recurrence of stroke-causing
thrombi might be reduced.
GLYCOPROTEIN VI
Glycoprotein (GP) VI is a platelet specific activatory receptor for
collagen and fibrin. Upon ligand binding, signals are transduced
via an immunoreceptor tyrosine-based activation motif (ITAM)
which is contained in the non-covalently associated Fc receptor
(FcR)γ-chain dimers that are part of the receptor complex (19,
52). Mice lacking GPVI, either by genetic deficiency of the
Gp6 gene or the FcRγ-chain or by antibody-mediated depletion
from the platelet surface, display defective platelet responses to
collagen but only a marginally impaired hemostasis, while they
are profoundly protected from arterial thrombosis (53, 54) and
experimental stroke (see Figure 1) (22). Morphological analysis
of the infarcted brain areas and MR imaging could exclude the
presence of intracerebral bleedings (22). The spleen tyrosine
kinase (Syk) acts downstream of ITAM-coupled receptors and is
therefore essential also for GPVI signaling. Upon ligand binding,
cross-linking of GPVI brings Fyn and Lyn (two Src family
tyrosine kinases) into contact with the FcRγ chain, which starts
a tyrosine phosphorylation cascade via Syk, linker of activated
T cells (LAT) and SLP-76 (SH2 domain containing leukocyte
protein of 76 kDa) leading to the activation of most notably
phospholipase (PL) C γ2 and phosphoinositide 3-kinases (PI3K)
(19). Syk not only acts downstream of GPVI but also CLEC-
2 and, in human platelets, FcγRIIA. In line with the results
from GPVI-deficient animals, Syk-deficient mice or mice that
were treated with a Syk-inhibitor, were protected from arterial
thrombosis and stroke but displayed only slightly increased
bleeding times. Of note, the animals were still protected, when
the treatment was given therapeutically, i.e., after induction
of the infarction (55). In accordance with the data reported
about the loss of ITAM-coupled receptors or signaling molecules,
a simultaneous loss of the ITAM inhibitory proteins SLAP
and SLAP2 dramatically aggravated neurological damage after
tMCAO (56).
The protection from arterial occlusion and stroke by GPVI
blockade without markedly increased risk of bleeding makes
GPVI a potentially attractive target for the treatment of stroke
patients in the clinic. Further, it could be shown that platelets
of patients with transient ischemic attack or stroke show an
elevated expression of GPVI on their surface when compared
to control patients (57). To block GPVI-collagen interaction in
the context of thrombosis, the GPVI-Fc fusion protein Revacept
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was developed and successfully tested in animal models, where
it protected mice from cerebral ischemia without inducing
intracranial hemorrhages (58). In a first study in healthy humans,
all doses were well-tolerated and neither prolonged bleeding time
nor thrombocytopenia have been observed. Platelet response to
collagen was inhibited in a time and dose-dependent manner,
whereas platelet aggregation in response to ADP or TRAP was
unaffected (59). The effect of Revacept in patients with carotid
artery stenosis, transient ischemic attack (TIA) or stroke is
currently tested in a phase II clinical study (NCT 01645306). A
second phase II study in patients with coronary artery disease has
been initiated and is in the phase of patient recruitment (NCT
03312855). Revacept binds to immobilized collagen and thereby
indirectly prevents platelet adhesion and activation at sites of
collagen exposure whereas it does not interact with fibrin (60).
ACT017 (9O12), a humanized Fab fragment against GPVI, which
was designed to directly inhibit GPVI on the platelet surface,
was shown to inhibit collagen-induced platelet aggregation ex
vivo and there were no signs of thrombocytopenia or excessive
bleeding (61). In addition to blocking the interaction of GPVI
with collagen, ACT017 has been shown to block spreading on
fibrinogen of human GPVI transgenic mouse platelets (62) and
reduces aggregate formation on fibrin in a model of venous
thrombosis (63). A phase II clinical trial investigating the effects
of ACT017 in patients with acute ischemic stroke is currently
under way (NCT 03803007).
PROTEASE-ACTIVATED RECEPTORS
(PARs) (THROMBIN RECEPTORS)
Thrombin activates platelets through the protease-activated
receptors (PARs) 3 and 4 inmice (PAR 1 and 4 in humans), which
transduce their signals via G-protein coupled receptors (Gq
and G12/13) thereby leading to platelet activation (64). Receptor
expression is not restricted to platelets; PARs are expressed in
a variety of tissues and cell types like bone marrow, spleen,
gastrointestinal tissues, lung, placenta, thyroid, prostate tissues,
and the brain, being involved in various cellular processes (65,
66). Thrombin at high concentrations can enter the brain as
a result of increased BBB permeability and acts on PARs that
are expressed in the central nervous system (on both, glial cells
and neurons). Focal ischemia induces the expression of PAR-
1 and PAR-3 on microglia and enhances PAR-4 labeling in the
penumbra (67). Since PAR-1 is not expressed in mouse platelets,
for initial experiments studying the role of platelet PAR-1, other
model systems have been used. In preclinical models using
cynomolgus monkeys, selective PAR-1 blockade led to potent
inhibition of thrombin-induced platelet aggregation without
impairing primary hemostatic function (68). A phase III clinical
trial (NCT 00526474) showed that the PAR-1 inhibitor vorapaxar
is beneficial in the secondary prevention of cardiovascular death
or ischemic events, but increases the risk of bleedings in patients
with a stroke history (69–71). Vorapaxar is approved for clinical
use but its use is limited by a substantial bleeding risk (72).
Another PAR-1 inhibitor, atopaxar has been shown to have a
good safety profile in terms of bleeding while reducing the
number of adverse ischemic events, but was not developed
further because it had not tolerable side effects on heart and
liver (73).
PAR4 is the only PAR member that is expressed on both,
human and murine platelets, and when Par-4−/− mice were
submitted to the tMCAO model, they displayed markedly
reduced infarct sizes, less neurologic impairment and reduced
BBB breakdown and cerebral edema formation (see Figure 1)
(74). Since PAR-4 in humans is responsive at higher thrombin
concentrations, it is hypothesized that initial platelet responses
to low thrombin concentration via PAR-1 are important for
hemostasis and later stages of platelet activation by thrombin
are important for occlusive thrombus formation and more
dependent on PAR-4. Targeting PAR-4 while maintaining PAR-
1 function might be more selective in preventing thrombotic
occlusion while maintaining hemostasis (75). A selective PAR-4
inhibitor (BMS-986120) was identified and tested in a monkey
model of occlusive arterial thrombosis, where it showed highly
efficacious antithrombotic activity, and although treated animals
had a slightly increased risk for bleeding, this was still markedly
reduced compared to clopidogrel (same study), abciximab or
cangrelor treated animals (75, 76). BMS-986120 was investigated
in phase I clinical trials (NCT02208882 and NCT02439190),
where a reduction in ex vivo platelet activation, aggregation
and thrombus formation could be observed without causing an
increase in coagulation times or serious adverse events (77).
For further clinical development, BMS-986120 is compared
with standard therapy in a phase II study of stroke recurrence
(NCT02671461) (78). Given the high abundance of PARs in
various tissues and cell types and the regulation of the expression
in pathological situations like ischemic stroke, targeting these
receptors might always have an influence on other cell types
either promoting the beneficial effect or, on the other hand,
leading to undesired side effects.
ADENOSINE DIPHOSPHATE (ADP)
RECEPTORS
ADP can activate platelets via three purinergic receptors,
P2Y1, P2Y12, and P2X1. P2Y1 and P2Y12 signal via G-
protein coupled receptors (Gαq and Gαi, respectively), and are
important for platelet shape change, aggregation, thromboxane
A2 generation, procoagulant activity, thrombus formation and
signal potentiation. P2X1 is an ion channel, that causes Ca
2+
influx upon activation but has negligible role for platelet plug
formation (79). Both, the P2Y1 and the P2Y12 receptor would be
potential targets for the treatment of platelet associated diseases.
However, P2Y1 is widely expressed, which increases the risk
of side effects, whereas P2Y12 expression is restricted to the
platelet surface and the brain, which makes it a more specific
target (79). P2Y12 inhibitors can be divided into thienopyridines
(like clopidogrel and prasugrel) and non-thienopyridines (like
ticagrelor and cangrelor). Thienopyridines require metabolic
activation and irreversibly inhibit the P2Y12 receptor, whereas
non-thienopyridines are already active and lead to a reversible
receptor inhibition. Treatment of mice with ticagrelor inhibited
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ADP induced platelet aggregation and reduced infarct sizes while
improving neurological function after tMCAO to a greater extent
than acetylsalicylic acid. Further, reperfusion of the infarcted
brain area was better as increased cerebral blood can bemeasured
in ticagrelor treated mice, compared to vehicle or acetylsalicylic
acid (aspirin R©) treatment (80). Likewise, P2Y12-deficient mice
displayed a slightly improved neurological outcome following
45min tMCAO as compared to wild-type control animals, albeit
the authors of that study ascribed the effect to P2Y12 in glia
cells (81).
In line with the data acquired for ticagrelor in mice,
in a non-human primate model of photochemically induced
thrombotic ischemic stroke, monkeys that received daily
treatments with prasugrel had significantly smaller infarcts and a
better neurological function without suffering from an increased
risk of hemorrhage (82). In clinical trials assessing the risk of
stroke recurrence subsequent to an initial thrombotic event, dual
antiplatelet therapy (DAPT) comprising acetylsalicylic acid and
clopidogrel was more efficient in reducing the risk of recurrent
events in the acute treatment of non-embolic TIA or ischemic
stroke (83, 84), but DAPT was not beneficial in the long-
term treatment of patients [reviewed in (85)]. In another study,
comparing ticagrelor with aspirin R©, ticagrelor was not found to
be superior to aspirin R© in reducing the occurrence of stroke,
myocardial infarction or death within the 90 days observation
period (83). However, in a study with patients suffering from
atherosclerosis, clopidogrel, and ticlopidine could provide a
better protection from stroke, myocardial infarction or vascular
death when compared to the aspirin R© treated cohort (86).
GLYCOPROTEIN-IIb/IIIa-RECEPTOR
Platelet GPIIb/IIIa (integrin αIIbβ3) is the most abundant
integrin on the platelet surface and mediates platelet adhesion
on the ECM by binding to its main ligand fibrinogen as
well as fibronectin and vitronectin. GPIIb/IIIa is essential
for platelet aggregation and thrombus formation by bridging
adjacent platelets via fibrinogen or, at high shear rates, vWF
(24). Given this important role, several GPIIb/IIIa inhibitors
have been developed to use its blockade in the prevention
of ischemic cardiovascular diseases. There are three approved
GPIIb/IIIa inhibitors, abciximab (a recombinant Fab fragment
of a monoclonal anti-GPIIb/IIIa antibody), eptifibatide (small
peptide), and tirofiban (small non-peptide compound) (87).
Several randomized controlled trials could show that the
currently available GPIIb/IIIa inhibitors are safe and efficiently
prevent complications in perioperative periods, which is why
they are recommended as routine emergency treatment for
thrombotic complications in ischemic heart disease (88, 89).
In the setting of ischemic stroke, however, blocking GPIIb/IIIa
in an experimental stroke model markedly increased the
risk of intracerebral hemorrhage and mortality and surviving
animals still showed infarct volumes that were in the range
of control treated mice. Decreasing the degree of receptor
blockade improved survival and reduced bleeding complications,
but had no impact on infarct size or neurological symptoms
(see Figure 1) (22). Notably, these data also largely exclude
thrombus formation (e.g., microthrombosis in cerebral vessels)
as a central mechanism underlying thrombo-inflammation and
infarct progression in the context of ischemic stroke.
Many clinical trials have been conducted assessing the use
of anti-GPIIb/IIIa inhibitors in the treatment of acute ischemic
stroke or the prevention of stroke [reviewed for tirofiban in (89)].
Although several studies verified the safety profile of tirofiban,
results are highly variable concerning beneficial effects of anti-
GPIIb/IIIa treatment for functional outcome and mortality. In
the setting of rescue stenting in the acute treatment of ischemic
stroke, stent patency correlated with tirofiban administration
without increasing intracranial hemorrhage or mortality (89, 90).
In other studies, however, GPIIb/IIIa inhibitors have been shown
to induce a significant increase in fatal intracerebral hemorrhage
as reported for tirofiban (91) and abciximab (23) and must
therefore be used with caution.
PLATELET GRANULE SECRETION
Platelets contain three major types of granules, namely α-
granules, dense granules and lysosomes, which secrete their
content upon platelet activation. α-granules account for roughly
10% of the total platelet mass being the most abundant
granule type (50–80 granules/mouse platelet) (92). They contain
more than 300 different proteins that play roles in diverse
processes such as coagulation, platelet adhesion, hemostasis,
wound healing, angiogenesis, host defense and tumor growth
(92). Dense granules are the second most abundant granule type
(5–6 granules/mouse platelet) and their name results from a
characteristic electron-dense spot seen in electron microscopic
analysis due to high concentrations of Ca2+, Mg2+, ADP, ATP,
and serotonin (93). All of these molecules act as second wave
mediators and promote the activation of platelets. Lysosomes
contain various proteolytic enzymes like proteases, glycosidases,
and cationic proteins with bactericidal activity proteins (94).
Dense Granule Secretion
Platelet activation results in the release of dense granule content,
such as ADP, ATP, serotonin, and calcium, amplifying the
activation response and promoting thrombus formation (92,
95). Mice lacking functional Munc13-4 (Unc13dJinx,Unc13d−/−)
display abolished platelet dense granule secretion resulting
in defective hemostasis and impaired experimental thrombus
formation (96–98). Following 1 h tMCAO, Unc13d−/− mice
had smaller infarcts and a better neurological outcome after
24 h compared to control mice (see Figure 1), which was
not accompanied by intra-cranial hemorrhages, indicating that
platelet dense granule secretion is not required to preserve
vascular integrity in the setting of acute cerebral ischemia (98).
Serotonin (5-hydroxytrytamine, 5-HT) is an important
neurotransmitter that has key functions within the brain and
in the periphery. Apart from the brain, 5-HT is synthetized
by tryptophan hydroxylase 1 (TPH1) by the enterochromaffin
cells of the gut (99). Platelets are the major pool for peripheral
serotonin, despite being unable to synthesize it; however, they
take serotonin up from the plasma and store it in their
dense granules (100). 5Htt−/− mice, which lack the serotonin
transporter, cannot store serotonin in the platelet dense granules
and display defective hemostasis and are protected in models
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of arterial thrombosis (101). In experimental stroke, however,
no differences were observed between 5Htt−/− and control
mice (101), indicating that abolished serotonin secretion is
not responsible for the reduced cerebral damage observed in
Unc13d−/− mice.
Given the well-established role of ADP/ATP in secondary
platelet activation (102), it seems more likely that the reduced
infarct sizes following brain I/RI in Unc13d−/− mice results
from the decreased platelet activation due to missing ADP/ATP
secretion in these animals. In line with this, ticagrelor-treated
mice displayed reduced infarct sizes and better neurological
outcome following tMCAO (80). Consequently, the primary
contribution of platelet dense granule secretion to cerebral
ischemia/reperfusion damage appears to be the amplification of
platelet activation.
Alpha Granule Secretion
Platelet α-granules contain more than 300 different proteins
involved not only in platelet adhesion but also inflammation,
angiogenesis and wound healing (92). The gray platelet
syndrome (GPS) is a rare, autosomal-recessive platelet disorder
characterized by thrombocytopenia, large platelets lacking α-
granules, and variable bleeding symptoms (103, 104). GPS has
been linked to mutations in the neurobeachin-like 2 gene
(NBEAL2) (105–107) and Nbeal2−/− mice mimic the hallmarks
of GPS (108–110). They were protected in models of arteriolar
thrombosis and ischemic stroke (see Figure 1) and displayed
prolonged tail bleeding times (108). Of note,Nbeal2−/− mice did
not display signs of spontaneous bleeding, nor was intracranial
hemorrhage within 24 h after cerebral ischemia observed (108).
We are not aware of any epidemiological studies that assessed the
occurrence of ischemic stroke in GPS patients compared to the
overall population. However, the results with Nbeal2−/− mice in
experimental stroke indicate that α-granule proteins contribute
to cerebral damage, but are not required for vascular integrity
following I/RI of the brain.
Interestingly, Unc13d−/−/Nbeal2−/− double KO mice,
which are unable to secrete their granule content showed an
impaired hemostatic response in the ischemic brain following
tMCAO, causing increased intracranial hemorrhage and
mortality (111). Platelet transfer experiments confirmed that
the platelet granule content is required to prevent intracranial
hemorrhage in these mice (111). Of note,Unc13d−/−/Nbeal2−/−
mice did not display a defective blood-brain barrier, nor
did these mice bleed in experimental models of skin or lung
inflammation, indicating that platelet granule content is of
particular importance to maintain the integrity of the cerebral
vasculature in the course of I/RI (111). The fact that Unc13d−/−
platelets display up to 60% reduced α-granule secretion at
threshold agonist concentrations (98) indicates that only a
small amount of α-granule-derived mediators is sufficient to
maintain vascular integrity during ischemic stroke. This is
supported by studies on thrombocytopenic mice revealing that
5% of normal platelet counts were still sufficient to prevent
intra-cranial bleedings in experimental models of focal cerebral
ischemia, while only severely thrombocytopenic mice (peripheral
platelet counts of <2.5% of control) suffered from intracranial
hemorrhages (22, 112, 113). Interestingly, a small fraction
of Unc13d−/−/Nbeal2−/− mice did not display intracranial
hemorrhages and these animals survived and had smaller
infarcts as compared to controls (111).
The plethora of platelet α-granule proteins and the fact that
the majority of them can also be released by other cells, makes
it challenging to identify the key components that contribute to
infarct progression following cerebral ischemia.
CONCLUSIONS AND PERSPECTIVES
The heterogeneity of stroke patients makes the development
of safe antiplatelet treatments challenging. Nevertheless,
experimental stroke studies suggest that targeting activatory
platelet receptors might be a feasible strategy to reduce thrombo-
inflammatory infarct progression following ischemic stroke. Due
to the fact that the expression of GPVI and GPIbα is limited to
platelets we consider these two receptors particularly interesting
in this aspect, as side-effects of their inhibition on other tissues
are unlikely. In particular, targeting the GPIbα-vWF interaction
could be a very attractive approach to inhibit pathogenic
platelet functions in acute ischemic stroke. According to this
hypothesis, blocking GPIbα would prevent platelet adhesion
and therefore the first step of platelet recruitment/activation
in the reperfused cerebral microcirculation. Moreover, GPIbα-
blockade also reduces the infiltration of immune cells into the
infarcted area and thereby inflammation (51) while not inducing
increased intracerebral hemorrhages, at least in the setting
of experimental focal ischemia (22). In contrast, GPIIb/IIIa
blockade is clearly a less favorable option as it is ineffective in
reducing thrombo-inflammation and a full receptor blockade
causes bleeding complications.
In the future, it will be of interest to investigate whether
thrombo-inflammatory mechanisms already contribute
to cerebral damage in the ischemic phase and whether
targeting them before recanalization would further reduce
infarct progression.
Likewise, treatment strategies that stimulate inhibitory
signaling pathways in platelets could be considered in the
context of ischemic stroke. Indeed, cilostazol an inhibitor of
phosphodiesterase-3 (PDE3), which dampens platelet activity
due to sustained levels of cyclic nucleotide monophosphate
(cAMP and cGMP), has been shown to reduce recurrent strokes
(114, 115). However, data from experimental studies argues that
the protective effect of PDE3-inhibitors might be independent of
platelet inhibition (116).
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